Cart
sales@molnova.com
Calycosin-7-O-beta-D-glucoside
CAS No. 20633-67-4
Calycosin-7-O-beta-D-glucoside( —— )
Catalog No. M13206 CAS No. 20633-67-4
Calycosin 7-O-β-D-glucoside has antimicrobial activity. Calycosin 7-O-β-D-glucoside is anticipated to be a promising anti-HIV agent.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 76 | In Stock |
|
| 10MG | 132 | In Stock |
|
| 25MG | 240 | In Stock |
|
| 50MG | 402 | In Stock |
|
| 100MG | 581 | In Stock |
|
| 500MG | 1197 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCalycosin-7-O-beta-D-glucoside
-
NoteResearch use only, not for human use.
-
Brief DescriptionCalycosin 7-O-β-D-glucoside has antimicrobial activity. Calycosin 7-O-β-D-glucoside is anticipated to be a promising anti-HIV agent.
-
DescriptionCalycosin 7-O-β-D-glucoside has antimicrobial activity. Calycosin 7-O-β-D-glucoside is anticipated to be a promising anti-HIV agent. It shows scavenging activity to DPPH radicals, and superoxide anion . Calycosin 7-O-β-D-glucopyranoside possesses an alleviating effect on osteoarthritis and can increase the fluidity of brain cell membrane in ischemia-reperfusion rats. Calycosin 7-O-β-D-glucopyranoside possesses a protective effect on rat hepatocytes, an inhibitory effect on COX-2 activity.(In Vitro):Calycosin-7-O-β-D-glucoside (2 μM; 6 hours) remarkably inhibits the expression and activities of MMPs, and secures the expression of cav-1 and tight junction proteins in the microvessels isolated from ischemic rat cortex.(In Vivo):Calycosin-7-O-β-D-glucoside (intraperitoneal injection; 26.8 mg/kg; 14 days) significantly reduces infarct volume, histological damage and BBB permeability in the in vivo MCAO ischemia-reperfusion rat model.
-
In VitroCalycosin-7-O-β-D-glucoside (2 μM; 6 hours) remarkably inhibits the expression and activities of MMPs, and secures the expression of cav-1 and tight junction proteins in the microvessels isolated from ischemic rat cortex.
-
In VivoCalycosin-7-O-β-D-glucoside (intraperitoneal injection; 26.8 mg/kg; 14 days) significantly reduces infarct volume, histological damage and BBB permeability in the in vivo MCAO ischemia-reperfusion rat model. Animal Model:Middle cerebral artery occlusion (MCAO) male adult Sprague-Daweley rats Dosage:26.8 mg/kg Administration:Intraperitoneal injection; 26.8 mg/kg; 14 days Result:Exhibited neuroprotective effects in rats.
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetMMP
-
RecptorMMP-2| MMP-9
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number20633-67-4
-
Formula Weight446.4
-
Molecular FormulaC22H22O10
-
Purity>98% (HPLC)
-
SolubilitySoluble in Pyridine, Methanol, Ethanol, etc.
-
SMILESCOC1=C(C=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Fu S, et al. J Ethnopharmacol. 2014 Aug 8;155(1):692-701.
molnova catalog
related products
-
Salvianolic acid A
Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.
-
MMP-9-IN-6
MMP-9-IN-6 is an MMP-9 inhibitor with an IC50 value of 50 μM and good anti-ulcer efficacy.MMP-9-IN-6 has potential anti-tumor activity and can be used to study tissue remodeling, wound repair and atherosclerosis.
-
PG-116800
PG-116800 (PG-530742) is a matrix metalloproteinase (MMP) inhibitor. PG-116800 can be used in studies about the treatment of osteoarthritis.
